Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.
about
Timing the emergence of resistance to anti-HIV drugs with large genetic barriersGeneration of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.Exploring the complexity of the HIV-1 fitness landscape.GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.HIV-1 Protease: Structural Perspectives on Drug ResistanceMolecular Basis for Drug Resistance in HIV-1 ProteasePulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.Spin labeling and Double Electron-Electron Resonance (DEER) to Deconstruct Conformational Ensembles of HIV Protease.Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitorsTracking the dynamics of salmonella specific T cell responses.Mechanism of HIV antiretroviral drugs progress toward drug resistance.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature reviewSynthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors.HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation ProcessBroad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease.Strategies for recognition of stem-loop RNA structures by synthetic ligands: application to the HIV-1 frameshift stimulatory sequence.Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world.Antiretroviral resistance in HIV-1 patients at a tertiary medical institute in Saudi Arabia: a retrospective study and analysis
P2860
Q28474857-42B7DE9A-DD1C-48A3-A819-32E6C25C0B02Q33990752-3BA9EB3B-036B-4D7E-AE8F-C67D035924E7Q34192888-8333F532-9D96-4344-90D3-11B6C033FE3EQ34737804-9FA09CB9-F493-42E7-B84E-36A625FD8852Q35259855-33773C49-49E2-45A2-966E-4B8E96EC9B42Q35260370-CD3F4ACC-99D4-4860-8E1D-954BB1FA7BAFQ36593975-34085029-6F6F-4B6B-A3F8-B2BA0B7F9CF7Q36664640-FD355690-8D70-4F00-AE16-2B5EEC4D464BQ37036823-E34801BF-2320-4582-993D-DFB89C6B4F16Q37517328-239D58C8-6817-4A03-BCBC-D6A0150D54A3Q37961181-EC0CCBBE-BAE0-4809-BB3F-DF60D09ACBD9Q38109095-8F661DB9-8369-4FBC-9162-6896AFF2B2A4Q38263521-7E6555BB-547A-47F3-9761-8CF129681DD8Q39396003-F2532DE9-EF69-49F5-813D-AA413100EA47Q39713096-9DA3FB8A-8E88-4BA4-9479-0AB2CD8A83AFQ41844750-498F8652-810A-44B2-8B76-E53A20620AA0Q42060329-FE47F08A-9548-4F88-8D6C-060B3A0DAC37Q42146547-894CB049-2A11-41EA-AF58-F9A1FCB3B4DBQ42485347-1675C037-6EA5-4EDE-9FAC-23F1CB806778Q46006854-37D00A9C-E866-455B-BC37-8B6679B75603Q57167106-B2045570-2EF2-4435-AA43-F8503BC33FBD
P2860
Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Protease inhibitor resistance ...... lar and clinical perspectives.
@en
type
label
Protease inhibitor resistance ...... lar and clinical perspectives.
@en
prefLabel
Protease inhibitor resistance ...... lar and clinical perspectives.
@en
P1433
P1476
Protease inhibitor resistance ...... lar and clinical perspectives.
@en
P2093
Jorge L Martinez-Cajas
Mark A Wainberg
P304
P356
10.1016/J.ANTIVIRAL.2007.06.010
P577
2007-07-16T00:00:00Z